Methenolone enanthateCAS# 303-42-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 303-42-4 | SDF | Download SDF |
| PubChem ID | 248271 | Appearance | Powder |
| Formula | C27H42O3 | M.Wt | 414.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(5S,8R,9S,10S,13S,14S,17S)-1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate | ||
| SMILES | CCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4C3(C(=CC(=O)C4)C)C)C | ||
| Standard InChIKey | TXUICONDJPYNPY-FRXWOFFRSA-N | ||
| Standard InChI | InChI=1S/C27H42O3/c1-5-6-7-8-9-25(29)30-24-13-12-22-21-11-10-19-17-20(28)16-18(2)27(19,4)23(21)14-15-26(22,24)3/h16,19,21-24H,5-15,17H2,1-4H3/t19-,21-,22-,23-,24-,26-,27-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Methenolone enanthate Dilution Calculator
Methenolone enanthate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.412 mL | 12.0598 mL | 24.1196 mL | 48.2393 mL | 60.2991 mL |
| 5 mM | 0.4824 mL | 2.412 mL | 4.8239 mL | 9.6479 mL | 12.0598 mL |
| 10 mM | 0.2412 mL | 1.206 mL | 2.412 mL | 4.8239 mL | 6.0299 mL |
| 50 mM | 0.0482 mL | 0.2412 mL | 0.4824 mL | 0.9648 mL | 1.206 mL |
| 100 mM | 0.0241 mL | 0.1206 mL | 0.2412 mL | 0.4824 mL | 0.603 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lasiocarpine
Catalog No.:BCN2001
CAS No.:303-34-4
- Heliotrine
Catalog No.:BCN1982
CAS No.:303-33-3
- Clinofibrate
Catalog No.:BCC5020
CAS No.:30299-08-2
- 2-Amino-N-(2-chloro-6-methylphenyl) thiazole-5-carboxamide
Catalog No.:BCC8551
CAS No.:302964-24-5
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- Ro 67-4853
Catalog No.:BCC7921
CAS No.:302841-89-0
- Ro 01-6128
Catalog No.:BCC7922
CAS No.:302841-86-7
- Ciliobrevin A
Catalog No.:BCC3939
CAS No.:302803-72-1
- TCS 46b
Catalog No.:BCC7482
CAS No.:302799-86-6
- 3,4,5-Trimethoxycinnamyl alcohol
Catalog No.:BCN5212
CAS No.:30273-62-2
- Bisline
Catalog No.:BCN2062
CAS No.:30258-28-7
- Rosiglitazone HCl
Catalog No.:BCC2269
CAS No.:302543-62-0
- Gossypol
Catalog No.:BCN2702
CAS No.:303-45-7
- Ochratoxin A
Catalog No.:BCC7008
CAS No.:303-47-9
- Coenzyme Q10
Catalog No.:BCN5954
CAS No.:303-98-0
- Pandamarilactonine A
Catalog No.:BCN5213
CAS No.:303008-80-2
- Pandamarilactonine B
Catalog No.:BCN5214
CAS No.:303008-81-3
- Picrasin B acetate
Catalog No.:BCN5215
CAS No.:30315-04-9
- TAK-715
Catalog No.:BCC3968
CAS No.:303162-79-0
- Centrolobol
Catalog No.:BCN5216
CAS No.:30359-01-4
- Dalbergioidin
Catalog No.:BCN4801
CAS No.:30368-42-4
- L-779,450
Catalog No.:BCC7593
CAS No.:303727-31-3
- U 18666A
Catalog No.:BCC7136
CAS No.:3039-71-2
- Reutericyclin
Catalog No.:BCN1855
CAS No.:303957-69-9
Aspergillus niger-mediated biotransformation of methenolone enanthate, and immunomodulatory activity of its transformed products.[Pubmed:27133901]
Steroids. 2016 Aug;112:68-73.
Two fungal cultures Aspergillus niger and Cunninghamella blakesleeana were used for the biotransformation of Methenolone enanthate (1). Biotransformation with A. niger led to the synthesis of three new (2-4), and three known (5-7) metabolites, while fermentation with C. blakesleeana yielded metabolite 6. Substrate 1 and the resulting metabolites were evaluated for their immunomodulatory activities. Substrate 1 was found to be inactive, while metabolites 2 and 3 showed a potent inhibition of ROS generation by whole blood (IC50=8.60 and 7.05mug/mL), as well as from isolated polymorphonuclear leukocytes (PMNs) (IC50=14.0 and 4.70mug/mL), respectively. Moreover, compound 3 (34.21%) moderately inhibited the production of TNF-alpha, whereas 2 (88.63%) showed a potent inhibition of TNF-alpha produced by the THP-1 cells. These activities indicated immunomodulatory potential of compounds 2 and 3. All products were found to be non-toxic to 3T3 mouse fibroblast cells.
Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin.[Pubmed:12801577]
Fertil Steril. 2003 Jun;79 Suppl 3:1659-61.
OBJECTIVE: To document for the first time the successful treatment using human chorionic gonadotropin (hCG) and human menopausal gonadotropins (hMG) of anabolic steroid-induced azoospermia that was persistent despite 1 year of cessation from steroid use. DESIGN: Clinical case report. SETTINGS: Tertiary referral center for infertility. PATIENT(S): A married couple with primary subfertility secondary to azoospermia and male hypogonadotropic hypogonadism. The husband was a bodybuilder who admitted to have used the anabolic steroids testosterone cypionate, methandrostenolone, oxandrolone, testosterone propionate, oxymetholone, nandrolone decanoate, and Methenolone enanthate. INTERVENTION(S): Twice-weekly injections of 10,000 IU of hCG (Profasi; Serono) and daily injections of 75 IU of hMG (Humegon; Organon) for 3 months. MAIN OUTCOME MEASURE(S): Semen analyses, pregnancy. RESULT(S): Semen analyses returned to normal after 3 months of treatment. The couple conceived spontaneously 7 months later. CONCLUSION(S): Steroid-induced azoospermia that is persistent after cessation of steroid use can be treated successfully with hCG and hMG.
The effects of testosterone propionate and methenolone enanthate on the healing of humeral osteotomies in the Wistar rat.[Pubmed:2285677]
J Invest Surg. 1990;3(2):93-113.
A randomized blind prospective study was carried out to determine if an anabolic androgenic steroid with a high anabolic/androgenic ratio, Group A, (1/0.05) Methenolone enanthate (me), compared to an anabolic/androgenic agent with a low anabolic/androgenic ratio, Group B, (1.0/1.0) testosterone propionate (tp), compared to a control, Group C, cottonseed oil (co), affected midhumeral osteotomy healing in 100 two-month-old female Wistar rats. The rats received 4 mg/kg me, 4 mg/kg te, and equal volumes of co weekly. The rats were sacrificed at 2, 4, and 6 weeks. The entire humerus with the healing osteotomy was carefully dissected until all soft tissue attachments were stripped. The healing callus was then subjected to (1) biochemical analysis (hexosamine, hydroxyproline, and calcium), (2) biomechanical testing (progressive distraction of the callus at 1 mm/min on an electrohydraulic materials test system, model 1331, Instron Corp, Canton, MA, and (3) histology. Results of the biochemical testing demonstrated that the percentage of calcium in the healing callus at 2 weeks in group B (tp) was 7.3 +/- 1.0, and this value was greater than that in group C (co), 4.8 +/- 1.6 (p greater than .01), and greater than that in group A (me), 5.6 +/- 0.6 (p greater than .01). At 4 weeks, the percentage of calcium in the callus in group B (tp) was 6.8 +/- 1.9, in group A (me) 7.3 +/- 3.7, and these values were both greater than that in group C (co), 3.9 +/- 2.2 (p greater than .02 and .01, respectively). At 6 weeks the percentage of calcium in the callus in group B (tp) was 11.7 +/- 3.9 and in group A (me) 12.7 +/- 3.9, and again these values were both greater than that in group C (co), 6.7 +/- 2.6 (p greater than .02 and .01, respectively). The remainder of the biochemical analysis, hexosamine and hydroxyproline content, did not show a statistical difference in groups A, B, and C at 2, 4, and 6 weeks. The biomechanical studies and histology also failed to show statistical differences between the three groups at 2, 4, and 6 weeks. The conclusion of this study is that an agent with a low androgenic activity does not increase calcium callus concentrations early in the course of fracture healing compared to an agent with higher androgenic activity. As healing progresses, both agents increase the concentration of calcium in osteotomy healing. The clinical significance of this study is that agents with low androgenic activities favorably influence osteotomy healing and may be clinically useful because they lack unwanted virilizing activity.
[Pathophysiology of aplastic anemia and its treatment with methenolone enanthate].[Pubmed:7467606]
Z Gesamte Inn Med. 1980 Nov 15;35(22):809-12.
For the development of an aplastic anaemia a large number of causes is taken into consideration. In our own clinical material of 26 patients in 15 patients none of the up to now known noxae could be established. Recently in the clarification of the picture of the disease important pathophysiological realizations were got. In these cases disturbances of the stem cell compartments, effects through the matrix of the haematopoietic cells and immunological processes have been recognized as significant. --Own investigations concerning the therapy with the anabolic metenolonenanthat (Primobolan-S) yielded approximately the same large number of therapeutic failures and patients with a good result of the treatment or a partial remission in 15 idiopathic and 11 toxically conditioned anaemias. In the partial remissions in most cases a thrombocytopenia continued existing. A therapy lasting at least two months is necessary in order to estimate the result of the therapy. At the present time cannot yet be predicted on which conditions the use of anabolics will be successful.
[Effect of an anabolic steroid (methenolone enanthate) on the intra- and extravasal albumin pool in liver cirrhosis].[Pubmed:1224752]
Z Gastroenterol. 1975 Oct;13(6):583-7.
15 patients with a histologically and/or peritoneoscopically proven cirrhosis of the liver were treated for four weeks with 200 mg metenolonenanthate (Depot-Primobolan) per week. Before and after the treatment the intravascular and extravascular pool and daily turnover of albumin were measured with 125J-albumin. All patients had a well "compensated" cirrhosis. The only significant difference between the values of the cirrhotic patients and those of a control group of patients was a reduction of the albumin turn-over. The anabolic steroid enlarged the turn-over, the effect was the more pronounced the more pronounced the more the turn over was diminished before the treatment.
